Real-world experience with cefepime/zidebactam under compassionate use
Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction: Cefepime/zidebactam is a β-lactam/β-lactam enhancer combination with activity against carbapenem-resistant (CR) Gram-negative pathogens, including metallo-β-lactamase (MBL)-producing organisms. Before regulatory approval, cefepime/zidebactam was available through a compassionate-use programme for patients with CR Gram-negative infections who had limited available treatment options. Methods: We conducted a retrospective, multi-country analysis of patients who received cefepime/zidebactam through compassionate use between 2022 and 2025. Data included demographics, comorbidities, acute complications, prior antibiotic exposure, infection characteristics, microbiology, treatment details, and investigator-assessed outcomes. Results: Eighty-five patients were included (median age 48 years; 57.6% in an intensive care unit at initiation). Primary infections included pneumonia/respiratory infection (30.6%), bone and joint infection (24.7%), and complicated urinary tract infection/pyelonephritis (14.1%). Pseudomonas aeruginosa was the predominant pathogen (77.6%), followed by Klebsiella pneumoniae (14.1%) and Acinetobacter baumannii (11.8%); infections involving at least two Gram-negative pathogens occurred in 10.6%. Among isolates with available genotypic data, MBLs were common and predominantly NDM. The cefepime/zidebactam minimum inhibitory concentration (MIC)50 and MIC90 were 8 and 32 mg/L, respectively. Investigator-assessed clinical success at the end of therapy was achieved in 88.2% of patients (95% CI, 79.7–93.5), and microbiological eradication in 89.4% (95% CI, 81.1–94.3); on-therapy mortality was 10.6% (95% CI, 5.7–18.9). Treatment-emergent adverse events occurred in five patients (5.9%, 95% CI, 2.5–13.0), with one discontinuation. Conclusions: In this uncontrolled compassionate-use case series, cefepime/zidebactam treatment was accompanied by high investigator-assessed clinical success and microbiological eradication in patients with severe infections caused by CR Gram-negative pathogens. These observations require confirmation in prospective controlled studies.
Source: UNC Libraries
DOI: 10.17615/9bwt-te51
Authors: Savla, Honey S, Singhal, Tanu, Kadnur, Harshith B, Agrawal, Umang, Krishna, Vidya, Tirlangi, Praveen K, Sebastian, Anjely P, Madan, Surabhi, Ghafur, Abdul, Lodise, Thomas P, Limaye, Harshad S, Sahu, Monalisa, Narreddy, Suneetha, Miller, William R, Toraskar, Kedar K, Manesh, Abi S, Aitken, Samuel L, Inamdar, Shalmali B, Patil, Pratik Y, Sridharan, Sowmya, Mitra, Sandeep K, Shah, Pooja H, Shetty, Siddhant, Veeraraghavan, Balaji, Rahulan, Vijil, Adderson, Elisabeth E, Gaikwad, Raman, Shorr, Andrew, Sunavala, Ayesha J, Soman, Rajeev, Mittal, Ankit, Soneja, Manish, Polati, Vishnu Rao, Deswal, Vikas, Dubey, Dilip K, Gupta, Neha, van Duin, David, Ulloa, Erlinda R, Mohammed, Irfana, Bansal, Nitin, Gupta, Nitin, Sarda, Radhika N, Swaminathan, Subramanian, Tayade, Ashwini R, Nagvekar, Vasant, Sirsat, Rasika, William, Timothy
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Microbiology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: cefepime/zidebactam, compassionate use, metallo-beta-lactamase, New Delhi metallo-beta-lactamase, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, beta-lactam/beta-lactamase inhibitor combinations, clinical success, microbiological eradication, treatment-emergent adverse events, intensive care unit patients, pneumonia, bone and joint infections
Open Access status: green
Funders: Purdue University, California Institute of Technology, Gun och Bertil Stohnes Stiftelse, Wellcome Trust, Ögonfonden, Stiftelsen Tornspiran, Ohio Soybean Council, Heritage Medical Research Institute, National Energy Research Scientific Computing Center, University of Leeds, Indian Council of Medical Research, Deutsche Forschungsgemeinschaft, National Natural Science Foundation of China, China Postdoctoral Science Foundation, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, China Scholarship Council, Norges Forskningsråd, Suzhou Municipal Science and Technology Bureau, Gansu University of Chinese Medicine, Narodowa Agencja Wymiany Akademickiej, Agencia Nacional de Investigación y Desarrollo, Ministero dell'Università e della Ricerca, National Institutes of Health, Office of Science, Engineering and Physical Sciences Research Council, Basic Research Program of Jiangsu Province, Sanming Project of Medicine in Shenzhen, National Key Research and Development Program of China, Institute for Materials Research, Tohoku University, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, Office of Advanced Cyberinfrastructure, Division of Chemical, Bioengineering, Environmental, and Transport Systems, Basic Energy Sciences, Fondo Nacional de Desarrollo Científico y Tecnológico, H2020 European Research Council
OpenAlex ID: W7235690786
